Surmodics

Provides components for diagnostics and medical devices

Eden Prairie, Minnesota, United States

About Surmodics

Surmodics specializes in providing essential components for in vitro diagnostic (IVD) products and advanced coatings for medical devices. Their IVD offerings include a variety of products such as protein stabilizers, diluents, blockers, substrates, and antibodies, which are vital for creating sensitive immunoassays that detect substances in biological samples. Surmodics also develops advanced coatings for medical devices, including lubricious and hemocompatible coatings, and is known for creating the drug delivery coating for the first drug-eluting stent. The company collaborates closely with clients to accelerate product development and commercialization, which helps them meet market demands quickly. Surmodics stands out from competitors through its strong focus on client collaboration and rapid product development, aiming to support the healthcare and biotechnology sectors effectively.

Eden Prairie, MinnesotaHeadquarters
1979Year Founded
$125MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
401(k) Company Match
401(k) Retirement Plan
Company Equity
Stock Options

Risks

GTCR acquisition may disrupt operations or client relationships.
Becoming privately held could reduce transparency and investor confidence.
New thrombectomy systems face competition, potentially impacting market share.

Differentiation

Surmodics excels in advanced coatings for medical devices, enhancing device performance.
The company offers a comprehensive range of IVD products for sensitive immunoassays.
Surmodics' expertise in drug-delivery coatings is unmatched, proven by the first drug-eluting stent.

Upsides

Surmodics' acquisition by GTCR could accelerate growth and innovation.
The launch of Pounce Thrombectomy Systems addresses rising peripheral artery disease cases.
Surmodics' SurVeil DCB shows promising results, boosting its vascular intervention portfolio.

Funding

Total raised$125.00 M
Latest valuation$627.00 M
StageIPO
BUYOUT
4/30/2024
$627
$627.00 M
POST IPO DEBT
9/30/2022
$125
ACQUISITION
10/31/2011
$30